Replies to post #425271 on Amarin Corp Plc (AMRN)

[Whalatane]

Its called research ...try it some time
Authorized generics face several challenges in making a profit in the US market:

Authorized generics are not subject to the rebates and discounts that branded drugs provide to PBMs and payers, making them appear more expensive from the payer's perspective despite a lower list price.
Launching an authorized generic can trigger higher Medicaid rebate penalties for the branded product under the Affordable Care Act's inflationary rebate provisions, offsetting potential profits from the authorized generic.
While authorized generics offer a modest price discount to cash-paying uninsured patients, they often do not provide significant savings to insured patients compared to the branded drug after accounting for rebates and out-of-pocket costs.

Kiwi